Sign Up
Stories
Spexis, NewAmsterdam, Molecure, and Cyclo Therapeutics: Key Updates in Biopharmaceutical Industry
Share
Amgen to Lay Off Horizon Employees After...
Biopharmaceutical Companies Merge and Pr...
Biopharmaceutical Merger and Presentatio...
ANJESO Drug Insight and Market Forecast
Acquisition Progress Amid Safety Concern
Advancements in Cancer Treatment and Mar...
Overview
API
Spexis AG announces changes to its Executive Committee, with Hernan Levett stepping down as Chief Financial Officer and Martin Jakobovic replacing him. NewAmsterdam Pharma appoints Ian Somaiya as Chief Financial Officer. Molecure reports significant financial and operational momentum, raising CHF 17.8 million in a secondary public offering and receiving FDA approval for clinical trials. Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. enter into a definitive merger agreement.
Ask a question
How will the appointment of Ian Somaiya as Chief Financial Officer impact NewAmsterdam Pharma?
What are the implications of the changes in Spexis AG's Executive Committee?
What are the potential outcomes of the merger between Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc.?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jun 2023
Jul 2023
Aug 2023
Sep 2023
Oct 2023
Coverage